AbbVie is investing $380 million to expand its US manufacturing capabilities, focusing on the production of active pharmaceutical ingredients for neuroscience and obesity medicines. This move is part of the company’s broader effort to scale up domestic manufacturing and reduce reliance on international supply chains.
On February 23, 2026, Reuters reported that AbbVie, a leading pharmaceutical company, announced plans to invest $380 million in expanding its US manufacturing capabilities. The investment will be used to build two new active pharmaceutical ingredient (API) manufacturing facilities at the company’s campus in North Chicago, Illinois. This expansion is expected to increase AbbVie’s domestic production capacity for its neuroscience and obesity medicines.
The decision to invest in US manufacturing comes as the pharmaceutical industry faces challenges related to global supply chains and tariffs on imported goods. The Trump administration’s imposition of a 100% tariff on branded drugs imported into the US has prompted companies like AbbVie to reconsider their manufacturing strategies. By expanding its domestic manufacturing capabilities, AbbVie aims to reduce its reliance on international supply chains and mitigate the risks associated with tariffs.
Expansion Details
The construction of the new facilities is scheduled to begin in spring 2026, with both facilities expected to be fully operational by 2029. The new facilities will integrate advanced manufacturing technologies and artificial intelligence to support the production of future pipeline medicines. AbbVie plans to hire 300 people in North Chicago, including engineers, scientists, manufacturing operators, and lab technicians, to support the expanded operations.
This investment is part of AbbVie’s broader commitment to US-based research and development. In January, the company announced a $100 billion investment over the next decade in US-based R&D, including a $195 million expansion at the same North Chicago site to boost API production for immunology, oncology, and neuroscience drugs. AbbVie already has 11 manufacturing sites in the US and is in discussions with multiple states about potential projects, with further investments expected to be announced in 2026.
Industry Implications
AbbVie’s decision to invest in US manufacturing reflects a broader trend in the pharmaceutical industry. As companies seek to reduce their reliance on international supply chains and mitigate the risks associated with tariffs, domestic manufacturing is becoming an increasingly attractive option. This shift is expected to have significant implications for the US economy, with the potential to create new jobs and stimulate local economies.
The use of advanced manufacturing technologies and artificial intelligence in the new facilities is also expected to improve the efficiency and quality of AbbVie’s manufacturing operations. As the pharmaceutical industry continues to evolve, the integration of these technologies is likely to become increasingly important for companies seeking to remain competitive.
For investors, AbbVie’s investment in US manufacturing is a positive development, demonstrating the company’s commitment to reducing its reliance on international supply chains and mitigating the risks associated with tariffs. As the company continues to expand its domestic manufacturing capabilities, it is likely to become an increasingly attractive option for investors seeking to capitalize on the growth of the US pharmaceutical industry.
To stay up-to-date on the latest developments in the pharmaceutical industry, including AbbVie’s ongoing expansion of its US manufacturing capabilities, visit onlytrustedinfo.com for the fastest, most insightful analysis of breaking financial news.
